

For further information, please visit: www.sparkventures.com
![]()
HBM BioVentures
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures’ portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the Swiss Stock Exchange (SIX: HBMN).
For further information, please visit: www.hbmbioventures.com

idinvest Partners
With €2.7 billion under management, IDinvest Partners (formerly AGF Private Equity) is a major actor in European venture capital and has invested in more than 80 companies to date. It has a regular, durable investment capacity investing more than €50 million each year in young businesses with strong potential. In all, the venture capital team manages more than €600 million. In September 2010, IDInvest Partners entered into an agreement with Kurma Life Sciences Partners under which Kurma manages the €87 million of biotechnology investments within the IDInvest porftfolio.
For further information, please visit: www.idinvestpartners.com and www.kurmabiofund.com
